Logo image of HSCS

HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HSCS - US42254E3027 - Common Stock

3.16 USD
+0.13 (+4.29%)
Last: 1/14/2026, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HSCS. HSCS was compared to 185 industry peers in the Health Care Equipment & Supplies industry. The financial health of HSCS is average, but there are quite some concerns on its profitability. HSCS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • HSCS had negative earnings in the past year.
  • In the past year HSCS has reported a negative cash flow from operations.
  • In the past 5 years HSCS always reported negative net income.
  • HSCS had a negative operating cash flow in each of the past 5 years.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

  • The Return On Assets of HSCS (-150.70%) is worse than 87.03% of its industry peers.
  • HSCS has a worse Return On Equity (-216.05%) than 73.51% of its industry peers.
Industry RankSector Rank
ROA -150.7%
ROE -216.05%
ROIC N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

  • HSCS has a Gross Margin (57.47%) which is in line with its industry peers.
  • HSCS's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for HSCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K

More info and screens

6

2. Health

2.1 Basic Checks

  • HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, HSCS has more shares outstanding
  • The number of shares outstanding for HSCS has been reduced compared to 5 years ago.
  • The debt/assets ratio for HSCS is higher compared to a year ago.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • HSCS has an Altman-Z score of -19.81. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
  • HSCS's Altman-Z score of -19.81 is on the low side compared to the rest of the industry. HSCS is outperformed by 88.11% of its industry peers.
  • There is no outstanding debt for HSCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.81
ROIC/WACCN/A
WACC9.74%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • HSCS has a Current Ratio of 2.42. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
  • HSCS's Current ratio of 2.42 is in line compared to the rest of the industry. HSCS outperforms 49.19% of its industry peers.
  • HSCS has a Quick Ratio of 2.00. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
  • HSCS has a Quick ratio of 2.00. This is comparable to the rest of the industry: HSCS outperforms 54.59% of its industry peers.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 74.25% over the past year.
  • The Revenue for HSCS has decreased by -76.34% in the past year. This is quite bad
  • Measured over the past years, HSCS shows a very negative growth in Revenue. The Revenue has been decreasing by -41.50% on average per year.
EPS 1Y (TTM)74.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.56%
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, HSCS will show a very strong growth in Earnings Per Share. The EPS will grow by 29.89% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.91%
EPS Next 2Y29.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2027 500K 1M 1.5M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • HSCS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSCS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HSCS's earnings are expected to grow with 29.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.89%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • HSCS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

HEARTSCIENCES INC

NASDAQ:HSCS (1/14/2026, 8:00:02 PM)

3.16

+0.13 (+4.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-15
Earnings (Next)N/A
Inst Owners5.51%
Inst Owner Change0%
Ins Owners3.68%
Ins Owner Change70.46%
Market Cap9.70M
Revenue(TTM)8.70K
Net Income(TTM)-9.04M
Analysts82.5
Price Target13.77 (335.76%)
Short Float %1%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.14%
Min EPS beat(2)18.47%
Max EPS beat(2)57.81%
EPS beat(4)3
Avg EPS beat(4)22.01%
Min EPS beat(4)-6.31%
Max EPS beat(4)57.81%
EPS beat(8)5
Avg EPS beat(8)-35.56%
EPS beat(12)7
Avg EPS beat(12)-27.5%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)55.77%
EPS NQ rev (3m)55.77%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1115.08
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB 4.12
EV/EBITDA N/A
EPS(TTM)-6.88
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0
BVpS1.36
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -150.7%
ROE -216.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.47%
FCFM N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 145.29%
Cap/Sales 460.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2
Altman-Z -19.81
F-Score3
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)199.15%
Cap/Depr(5y)121.34%
Cap/Sales(3y)570.65%
Cap/Sales(5y)345.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.56%
EPS Next Y30.91%
EPS Next 2Y29.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.17%
OCF growth 3YN/A
OCF growth 5YN/A

HEARTSCIENCES INC / HSCS FAQ

What is the fundamental rating for HSCS stock?

ChartMill assigns a fundamental rating of 2 / 10 to HSCS.


Can you provide the valuation status for HEARTSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to HEARTSCIENCES INC (HSCS). This can be considered as Overvalued.


What is the profitability of HSCS stock?

HEARTSCIENCES INC (HSCS) has a profitability rating of 1 / 10.